Global /Türkiye /Healthcare /Drug Manufacturers - General /GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi

GENIL

• IST: GENIL • Delayed

9.79TRY 1.2%

0.2123 USD

As of 11 June 2026, Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has a market cap of $943.17M USD, ranking #11033 globally and #89 in Türkiye. It ranks #996 in the Healthcare sector, and #373 in the Drug Manufacturers - General industry.

Global Rank

11033

Country Rank

Sector Rank

996

Industry Rank

373

Key Stats

Market Cap

$943.17MUSD

43.52B TRY

Enterprise Value

$965.07MUSD

44.51B TRY

Revenue (TTM)

$415.75MUSD

19.18B TRY

EBITDA (TTM)

$62.17MUSD

2.87B TRY

Net Income (TTM)

$17.65MUSD

814.44M TRY

EBITDA Margin

15%

Profit Margin

4.2%

PE Ratio

63.7

PS Ratio

2.3

PB Ratio

4.2

EV/EBITDA

15.5

Company Profile

Country (HQ)

Türkiye

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Abidin Gulmus open_in_new

Employees

682

Founded

1997

Website

genilac.com.tr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.2%	-1.4%	1.3%	18%	-22%	-26%	25%	229%	930%

News

Markets

Exchange	Ticker	Price	Quotes
Borsa Istanbul (IST / BIST) MIC: XIST PRIMARY	GENIL GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. ISIN: TREGENL00024 Shares Out.: Shares Outstanding: 4.49B¹ Shares Float: 1.083B² TV: TradingView: BIST: GENIL SA: Stock Analysis: IST: GENIL YF: Yahoo Finance: GENIL.IS GF: Google Finance: IST: GENIL BA: Barron's: GENIL MS: Morningstar: XIST: GENIL	9.79 TRY	TV: TradingView: BIST: GENIL SA: Stock Analysis: IST: GENIL YF: Yahoo Finance: GENIL.IS GF: Google Finance: IST: GENIL BA: Barron's: GENIL MS: Morningstar: XIST: GENIL

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.

Similar Companies

Industry: Drug Manufacturers - General (Türkiye)

Name	Market Cap (USD) diff.	PE	Country
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. IST: ECILC	$1.27B 58.69B TRY 35%	28.1	Türkiye
Deva Holding A.S. IST: DEVA	$292.63M 13.5B TRY -69%	-	Türkiye
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi IST: ONCSM	$148.88M 6.87B TRY -84%	136.3	Türkiye
Turk Ilac Ve Serum Sanayi Anonim Sirketi IST: TRILC	$32.82M 1.51B TRY -97%	-	Türkiye

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 81K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 58K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 38K%	97.4	United States
Roche Holding AG SIX: RO	$320.56B 256.25B CHF 34K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.45B 215.59B GBP 30K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 29K%	15.1	United States

chevron_leftBack